Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study.
Schenk JM, Liu M, Neuhouser ML, Newcomb LF, Zheng Y, Zhu K, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Wagner AA, Lin DW. Schenk JM, et al. Among authors: wagner aa. Nutr Cancer. 2023;75(2):618-626. doi: 10.1080/01635581.2022.2143537. Epub 2022 Nov 7. Nutr Cancer. 2023. PMID: 36343223 Free PMC article.
Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator.
Ankerst DP, Xia J, Thompson IM Jr, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, Lin DW. Ankerst DP, et al. Among authors: wagner aa. Eur Urol. 2015 Dec;68(6):1083-8. doi: 10.1016/j.eururo.2015.03.023. Epub 2015 Mar 25. Eur Urol. 2015. PMID: 25819722 Free PMC article. Clinical Trial.
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.
Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW; Canary PASS Investigators. Newcomb LF, et al. Among authors: wagner aa. J Urol. 2016 Feb;195(2):313-20. doi: 10.1016/j.juro.2015.08.087. Epub 2015 Aug 29. J Urol. 2016. PMID: 26327354 Free PMC article.
Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study.
Macleod LC, Ellis WJ, Newcomb LF, Zheng Y, Brooks JD, Carroll PR, Gleave ME, Lance RS, Nelson PS, Thompson IM Jr, Wagner AA, Wei JT, Lin DW. Macleod LC, et al. Among authors: wagner aa. J Urol. 2017 Apr;197(4):1026-1033. doi: 10.1016/j.juro.2016.10.090. Epub 2016 Nov 1. J Urol. 2017. PMID: 27810448 Free PMC article.
Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, Carroll PR, Cooperberg M, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y; Canary Prostate Active Surveillance Study Investigators. Lin DW, et al. Among authors: wagner aa. Eur Urol. 2017 Sep;72(3):448-454. doi: 10.1016/j.eururo.2016.11.017. Epub 2016 Nov 23. Eur Urol. 2017. PMID: 27889277 Free PMC article. Clinical Trial.
Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
Kearns JT, Faino AV, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, Lin DW. Kearns JT, et al. Among authors: wagner aa. Eur Urol. 2018 May;73(5):706-712. doi: 10.1016/j.eururo.2018.01.016. Epub 2018 Feb 9. Eur Urol. 2018. PMID: 29433973 Free PMC article.
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y. Cooperberg MR, et al. Among authors: wagner aa. Eur Urol. 2018 Aug;74(2):211-217. doi: 10.1016/j.eururo.2018.01.017. Epub 2018 Feb 9. Eur Urol. 2018. PMID: 29433975 Free PMC article.
Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).
Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW. Newcomb LF, et al. Among authors: wagner aa. Prostate Cancer Prostatic Dis. 2019 Sep;22(3):438-445. doi: 10.1038/s41391-018-0124-z. Epub 2019 Jan 21. Prostate Cancer Prostatic Dis. 2019. PMID: 30664734 Free PMC article.
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, Trinh QD, Chang SL, Harshman LC, Ross AE, Pienta KJ, Lin DW, Ellis WJ, Montgomery B, Chang P, Wagner AA, Bubley GJ, Kibel AS, Taplin ME. McKay RR, et al. Among authors: wagner aa. J Clin Oncol. 2019 Apr 10;37(11):923-931. doi: 10.1200/JCO.18.01777. Epub 2019 Feb 27. J Clin Oncol. 2019. PMID: 30811282 Free PMC article. Clinical Trial.
129 results